Evidence map›Paper›PMID 41224653›Full record

ReviewThe Journal of neuroscience : the official journal of the Society for Neuroscience2025

APOE-Targeted Therapeutics for Alzheimer's Disease.

Hussein N Yassine, Cristelle Hugo, Bernadette O'Donovan, Isaiah O Stephens, Lance A Johnson, Gregory Cole, Julia Tcw, Jan Johansson, Kassandra Kisler, Ornit Chiba-Falek

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Exploring the Neuroprotective Effects of Walnut (International journal of molecular sciences · 2026
    Article
  2. Reframing Alzheimer's Disease Through a Redox-Metabolic Framework.International journal of molecular sciences · 2026
    Review
  3. Article
  4. TMEM106B is a selective modulator of TDP-43 pathology in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Plasma Proteomic Analysis ofmedRxiv : the preprint server for health sciences · 2026
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hussein N YassineDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033 hyassine@usc.edu o.chibafalek@duke.edu.ORCID 0000-0002-2483-649X
Cristelle HugoDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033.
Bernadette O'DonovanDivision of Translational Brain Sciences, Department of Neurology, Duke University School of Medicine, Durham, North Carolina 27710.
Isaiah O StephensDepartment of Physiology, University of Kentucky, Lexington, Kentucky 40508.ORCID 0009-0007-7070-1805
Lance A JohnsonDepartment of Physiology, University of Kentucky, Lexington, Kentucky 40508.ORCID 0000-0003-0134-7586
Gregory ColeDepartment of Neurology and Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095.
Julia TcwDepartment of Pharmacology, Physiology & Biophysics, Chobanian & Avedisian School of Medicine, Boston University, Boston, Massachusetts 02118.ORCID 0000-0002-3054-9374
Jan JohanssonArtery Therapeutics, Inc., San Ramon, California 94583.
Kassandra KislerDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90033.ORCID 0000-0002-4161-2498
Ornit Chiba-FalekDivision of Translational Brain Sciences, Department of Neurology, Duke University School of Medicine, Durham, North Carolina 27710 hyassine@usc.edu o.chibafalek@duke.edu.ORCID 0000-0002-2529-8785

Funding

Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Daniel A Nation, ARTHUR W TOGA · 2016 to 2026
$28.4M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathiesP20GM148326 · NIGMS · UNIVERSITY OF KENTUCKY · PI Patrick G Sullivan · 2023 to 2026
$10.6M
Alzheimer's Abeta, Tau, Apolipoproteins and Blood-brain barrierR01NS034467 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 1995 to 2024
$9.1M
The delivery of essential fatty acids to the Brain in Alzheimer's diseaseR01AG054434 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$5.4M
Biomarkers of ABCA1 mediated functions in Alzheimers diseaseR01AG055770 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$4.2M
ApoE, ABCA1 and endosomal dysregulation in ADR01AG067063 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2020 to 2024
$3.4M
Elucidating endolysosomal trafficking dysregulation induced by APOE4 in human astrocytesR01AG082362 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.3M
Microglia targeted interventions in prodromal Alzheimer's disease stageR01AG083941 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.2M
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253R44AG076299 · NIA · ARTERY THERAPEUTICS, INC. · PI JOHANSSON, JAN · 2021 to 2023
$3.0M
CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's diseaseR44AG060826 · NIA · ARTERY THERAPEUTICS, INC. · PI JOHANSSON, JAN · 2019 to 2020
$2.9M
APOE Allele Switching as a Therapeutic Approach for Alzheimer's DiseaseR01AG080589 · NIA · UNIVERSITY OF KENTUCKY · PI Lance Allen Johnson · 2023 to 2026
$2.6M
NIA NIH HHS P01 AG052350NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG054434NIA NIH HHS R01 AG055770NIA NIH HHS R01 AG062550NIA NIH HHS R01 AG067063NIA NIH HHS R01 AG080589NIA NIH HHS R01 AG081421NIA NIH HHS R01 AG082362NIA NIH HHS R01 AG083941NIA NIH HHS R21 AG056518NIA NIH HHS R41 AG077992NIA NIH HHS R44 AG060826NIA NIH HHS R44 AG076299NIA NIH HHS RF1 AG076124NIA NIH HHS RF1 AG077695NIGMS NIH HHS P20 GM148326NINDS NIH HHS R01 NS034467
6 · The paper itself

Abstract

Apolipoprotein E (APOE) is the major lipid transport protein in the brain. Produced primarily by astrocytes and microglia, it delivers cholesterol and other lipids for membrane repair, synaptic maintenance, and immune regulation. Through interactions with specific lipid receptors, APOE maintains neuronal and vascular health. The

Indexed as

Alzheimer DiseaseApolipoprotein E4Apolipoproteins EAnimalsBlood-Brain BarrierGenetic TherapyHumansApolipoprotein E4Apolipoproteins E

Identifiers

PMID41224653
PMCPMC12614056

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.